Ranbaxy Laboratories (Delisted) share news and announcements
BSE: 500359
Last traded ₹859.80 on 1 Apr 2015
Delisted on 30 Mar 2016.
Ranbaxy Laboratories share news and announcements
790 announcements, routine notices left out, newest first. Page 4 of 16.
Mar 2014
14 Mar · Rating
Credit Analysis & Research Limited (CARE), has revised credit rating for long term debt instruments issued by the Company, from CARE AA+ (DoubIe ....
Feb 2014
25 Feb · Updates
Company is currently examining processes and controls at all Company's Active Pharmaceutical Ingredients (API) Manufacturing and Quality units. This action has led to temporarily putting on hold shipments from Company's API facilities of the Toansa and Dewas Plants.This voluntary decision was taken as a precautionary measure and out of abundant caution to better allow the Company to assess and review the processes and controls. The Company will resume shipments after reassuring them about the processes and controls at these facilities. In the meanwhile, a committee of the Board has been constituted in February 2014 as the "Quality & Integrity Committee". The Committee's objective is to help and assure good governance to all Ranbaxy stakeholders. Its primary role is to provide oversight on the Company's manufacturing and quality operations, systems, organization and integrity.25 Feb · Updates
Company is currently examining processes and controls at all Company's Active Pharmaceutical Ingredients (API) Manufacturing and Quality ....
Jan 2014
24 Jan · Press Statement
17 Jan · Legal
Ranbaxy Laboratories Ltd has clarified to BSE as under:- "We wish to inform you that while we do not disclose individual business transactions as a part of our normal course of business, ....13 Jan · Legal
Ranbaxy Laboratories Ltd has clarified to BSE as under:- "On Saturday, January 11, 2014, Ranbaxy received the form 483 with certain observations as a result of the recent US FDA ....13 Jan · Legal
Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "USFDA probes Ranbaxy units - API mftg unit in Toansa". The Company has clarified that "On Saturday, January 11, 2013, Ranbaxy received the form 483 with certain observations as a result of the recent US FDA inspection at its API plant at Toansa, Punjab, India. The Company is assessing the observations, and will respond to the US FDA in accordance with the agency s procedure to resolve the concerns at the earliest. Ranbaxy continues to improve its systems and processes, and remains fully committed to upholding the highest standards that patients, prescribers, regulators and all other stakeholders expect from the Company. Ranbaxy stays firmly committed to its philosophy of Quality and Patients First ".10 Jan · Business
ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 10, 2014, allotted 37,281 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,779,063 Equity Shares of Rs.5 each aggregating Rs, 2,118,895,315/-.10 Jan · Allotment of Equity Shares
ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 10, 2014, allotted 37,281 Equity Shares on exercise ....8 Jan · Board meeting
Inter-alia to consider and approve Standalone and Consolidated Unaudited Financial Results for the fourth quarter and twelve months period ended December 31, 2013 as reviewed by the Statutory Auditors of the Company. Further, the Company had changed its financial year from January-December to April-March effective April 01, 2014 and therefore current financial year will be for a period of 15 months i.e. January, 2013 to March, 2014.8 Jan · Results
Meeting of the Board of Directors of the Company will be held on February 05, 2014, inter alia, to consider and approve Standalone and Consolidated ....8 Jan · Ranbaxy receives approval to market RAN Donepezil in Canada
Dec 2013
12 Dec · Legal
With reference to news item titled "Pharma CEO Kin stocking up on Ranbaxy Shares" which appeared in Economic Times dated December 12, 2013. In this regard, Ranbaxy Laboratories Ltd ....11 Dec · Business
Allotment Committee of Directors through Resolution by Circulation passed on December 11. 2013, allotted 600,000 Equity Shares of Rs. 5 each for cash at par to Ranbaxy ESOP Trust (Trust), set up to administer Ranbaxy Employee Stock Option Plan-2011. The Trust would allocate the shares to the employees of the Company and of its subsidiaries on exercise of stock options from time to time under Ranbaxy Employee Stock Option Plan - 2011.The paid-up Equity Share Capital of the Company post allotment is 423,741,782 Equity Shares of Rs. 5 each aggregating Rs. 2,118,708,910/-.11 Dec · Allotment of Equity Shares
Allotment Committee of Directors through Resolution by Circulation passed on December 11. 2013, allotted 600,000 Equity Shares of Rs. ....
Nov 2013
20 Nov · Ranbaxy Completes 20 Years In Ukraine
Oct 2013
29 Oct · Board meeting
Board of Directors of the Company at its meeting held on October 29, 2013 have approved change of financial year of the Company from January-December to April-March effective April 01, 2014. In view of this, the current financial year will be for a period of 15 months i.e. January, 2013 to March, 2014.29 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2013 as follows: Net Sales of Rs. 275017.4 lacs for the quarter ending on 30-SEP-2013 against Rs. 263320.3 lacs and Rs. 265139.1 lacs for the quarters ending on 30-JUN-2013 and 30-SEP-2012 respectively. Net Profit / (Loss) of Rs. (45416.9) lacs for the quarter ending on 30-SEP-2013 against Rs. (52424.4) lacs and Rs. 75417.3 lacs for the quarters ending on 30-JUN-2013 and 30-SEP-2012 respectively.29 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2013 as follows: Net Sales of Rs. 138184.2 lacs for the quarter ending on 30-SEP-2013 against Rs. 139509.6 lacs and Rs. 142803.8 lacs for the quarters ending on 30-JUN-2013 and 30-SEP-2012 respectively. Net Profit / (Loss) of Rs. (84223.2) lacs for the quarter ending on 30-SEP-2013 against Rs. (60880.9) lacs and Rs. 55219.2 lacs for the quarters ending on 30-JUN-2013 and 30-SEP-2012 respectively.29 Oct · Limited Review for Sept 30, 2013
29 Oct · Board meeting
Board of Directors of the Company at its meeting held on October 29, 2013, inter alia, have approved the following: - Change of ....11 Oct · Allotment of Equity Shares
ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on October 11, 2013, allotted 12,273 Equity Shares on exercise ....
Sep 2013
27 Sep · Rating
ICRA has assigned the rating of "[ICRA]A1+" (pronounced as A One Plus) to the Company's Commercial Paper (CP)/Short Term Debt (STD) programme for an enhanced amount of Rs. 800 Crores. Earlier CP/STD programme of the Company for Rs.1200 Crores was also assigned the same rating i.e. "[ICRA]A1+" . Instruments with "[ICRA]A1+" rating are considered to have very strong degree of safety regarding timely payment of financial obligations. Such instruments carry lowest credit risk.27 Sep · Rating
ICRA has assigned the rating of “[ICRA]A1+” (pronounced as A One Plus) to the Company’s Commercial Paper (CP)/Short Term Debt (STD) programme ....